공시 • Apr 10
eXoZymes, Inc. has filed a Follow-on Equity Offering. eXoZymes, Inc. has filed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock 공시 • Mar 26
eXoZymes, Inc. to Report Q4, 2025 Results on Mar 31, 2026 eXoZymes, Inc. announced that they will report Q4, 2025 results on Mar 31, 2026 New Risk • Dec 28
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$96.4m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Earnings have declined by 51% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$96.4m market cap). 공시 • Jun 23
eXoZymes, Inc., Annual General Meeting, Jul 25, 2025 eXoZymes, Inc., Annual General Meeting, Jul 25, 2025. New Risk • Jun 22
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$76.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$10m free cash flow). Earnings have declined by 52% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Market cap is less than US$100m (US$76.6m market cap). 공시 • Apr 11
eXoZymes Inc. Announces Its Latest Initiative BioClick eXoZymes Inc. announced its latest initiative - BioClick - a pioneering concept designed to enhance and accelerate the engineering of enzymes for advanced chemical reactions. Funded in part by a $300K grant from the National Institutes of Health (NIH), this project has the potential to revolutionize how medicines and other bio-based compounds are created. At the heart of BioClick is a focus on group transfer reactions, a class of biochemical reactions that allow enzymes to precisely move small molecular chemical groups from one compound to another. Inspired by the 2022 Nobel Prize in Chemistry concept of Click Chemistry, often described as snapping LEGO pieces together, BioClick is now enabling new types of group transfers using custom enzymes. Among these, prenylation is a standout: a process where a small fatty molecular group is taken from a donor molecule and added to another drug compound to improve its function or how well it works in the body. This technique is especially promising in the development of more effective, targeted drugs and therapies, either as new drugs or as better versions of existing drugs. Critically, the BioClick tools also introduce new high-throughput screening capabilities, allowing researchers to test thousands of enzyme variations simultaneously. With the help of advanced tools like mass spectrometry and cutting-edge data analysis algorithms, eXoZymes can quickly identify which enzyme version works best for a given group transfer reaction - greatly enhancing the molecular level operation by quickly identifying the best-performing variants. This Artificial Evolution process dramatically reduces the time and cost required to develop the exozyme pathway that will produce a new or better drug. 공시 • Apr 03
eXoZymes Inc. Appoints Damien Perriman as Chief Commercial Officer eXoZymes Inc. announced the appointment of Damien Perriman to a newly created role as Chief Commercial Officer (CCO). Perriman brings more than two decades of experience in successfully commercializing several biotechnologies, spanning diverse markets such as nutrition, personal care, plastics, textiles, fragrances, performance fuels, and specialty chemicals. Before joining eXoZymes, Perriman most recently has served leading commercial roles at both Genomatica (Geno) and Gevo, while also serving as Chairman of the Board of Danish biotechnology startup Cellugy. New Risk • Mar 28
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$96.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.9m free cash flow). Negative equity (-US$3.6m). Revenue has declined by 101% over the past year. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$96.5m market cap). 공시 • Mar 27
eXoZymes, Inc. to Report Q4, 2024 Results on Apr 02, 2025 eXoZymes, Inc. announced that they will report Q4, 2024 results on Apr 02, 2025 공시 • Feb 23
eXoZymes, Inc. Announces Management Changes On February 17, 2025, Mr. Mohammad Hayat, a member of the Board of Directors of eXoZymes Inc. as well as its President and Chairman of the Board, resigned from the Board and from all positions he held in the Company. On February 17, 2025, the Board appointed Mr. Edgardo Rayo as a member of the Board to fill the vacancy created by Mr. Hayat’s resignation. There is no current arrangement in place for compensation to Mr. Rayo as a director. The Board also appointed Mr. Christopher A. Marlett as the Chairman of the Board on the same date. New Risk • Jan 17
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$99.7m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.9m free cash flow). Negative equity (-US$3.6m). Revenue has declined by 101% over the past year. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (18% average weekly change). Market cap is less than US$100m (US$99.7m market cap). 